Page 153 - Haematologica3

Experiences from the Swedish Myeloma Registry
survival in MM patients are compromised by the report- ing bias of referral centers, either because they are univer- sity hospital registries with a low median age at MM diag- nosis, or because they report on selected patients in clini- cal trials who do not necessarily, therefore, reflect the 'real-world' scenario in myeloma. Great efforts are being made to ensure the data available in the Swedish Myeloma Registry are complete, and to present popula-
tion-based data on management and outcome in Sweden. However, we can now present a near complete 'real- world' population of myeloma patients, and show that the overall incidence and median age is higher than in most previous studies, indicating a more complete cover- age of older patients. Myeloma survival in Sweden was similar to other large registry studies, and responses and survival improved over the study period.
References
1. Bird J, Behrens J, Westin J, et al. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M- proteins and the management of monoclon- al gammopathy of undetermined signifi- cance (MGUS). Br J Haematol. 2009;147(1):22-42.
2. Rajkumar SV. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol. 2013; 88(3):226-235.
3. Kristinsson SY, Anderson WF, Landgren O. Improved long-term survival in multiple myeloma up to the age of 80 years. Leukemia. 2014;28(6):1346-1348.
4. Gay F, Larocca A, Wijermans P, et al. Complete response correlates with long- term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients, Blood. 2011;117(11):3025-3031.
5. SanMiguelJF,SchlagR,KhuagevaNK,etal. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906-917.
6. Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III tri- als of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009; 23(11):2147- 2152.
7. Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Bjorkholm M. Patterns of sur- vival in multiple myeloma: a population- based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol. 2007;25(15):1993-1999.
8. Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in mul- tiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122-1128.
9. De Angelis R, Minicozzi P, Sant M, et al. Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000-2007: Results of EUROCARE-5 population-based study. Eur J Cancer. 2015;51(15):2254-2268.
10. KristinssonS,etal.Improvedlong-termsur- vival in multiple myeloma up to the age of
80 years. Leukemia. 2014;28(6):1346-1348.
11. Pulte D, Gondos A, Brenner H. Improvement in Survival of Older Adults with Multiple Myeloma: Results of an Updated Period Analysis of SEER Data.
Oncologist. 2011;16(11):1600-1603.
12. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma.
Blood. 2008;111(5):2521-2526.
13. Turesson I, Velez R, Kristinsson SY,
Landgren O. Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clin- ic. Mayo Clin Proc. 2010;85(3):225-230.
14. Turesson I, Velez R, Kristinsson SY, Landgren O. Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol. 2010;28(5):830-834.
15. Turesson I, Linet MS, Bjorkholm M, et al. Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malig- nancies in Sweden 1964-2003. Int J Cancer. 2007;121(10):2260-2266.
16. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412- 3420.
17. Smith A, Wisloff F, Samson D, et al. Guidelines on the diagnosis and manage- ment of multiple myeloma 2005. Br J Haematol. 2006;132(4):410-451.
18. Socialstyrelsen. Available from: http: //www.socialstyrelsen.se/statistics/statisti- caldatabase/cancer.
19. The completeness of the Swedish Cancer Register – a sample survey for year 1998. Acta Oncol. 2009;48(1):27-33.
20. Pohar M, Stare J. Relative survival analysis in R. Comput Programs Biomed. 2006;81(3):272-278.
21. R Core Team R Foundation for Statistical Computing V, Austria. R: A language and environment for statistical computing, 2016.
22. Alexander DD, Mink PJ, Adami HO, et al. Multiple myeloma: a review of the epidemi- ologic literature. Int J Cancer. 2007;120(Suppl 12):40-61.
23. Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116(19):3724-3734.
24. Velez R, Turesson I, Landgren O, Kristinsson SY, Cuzick J. Incidence of multiple myeloma in Great Britain, Sweden, and Malmo, Sweden: the impact of differences in case ascertainment on observed incidence trends. BMJ. 2016;6(1):e009584.
25. Gimsing P, Holmstrom MO, Klausen TW, et al. The Danish National Multiple Myeloma Registry. Clin Epidemiol. 2016;8:583-587.
26. Yong K, Delforge M, Driessen C, et al. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol. 2016; 175(2):252-264.
27. Sant M, Minicozzi P, Mounier M, et al. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a popula- tion-based study. Lancet Oncol. 2014; 15(9):931-942.
28. Micheli A, Ciampichini R, Oberaigner W, et al. The advantage of women in cancer sur- vival: An analysis of EUROCARE-4 data. Eur J Cancer. 2009;45(6):1017-1027.
29. Lahuerta JJ, Paiva B, Vidriales MB, et al. Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. J Clin Oncol. 2017;35(25):2900-2910.
30. van de Velde H, Londhe A, Ataman O, et al. Association between complete response and outcomes in transplant-eligible myeloma patients in the era of novel agents. Eur J Haematol. 2017;98(3):269-279.
31. Landgren O, Iskander K. Modern multiple myeloma therapy: deep, sustained treat- ment response and good clinical outcomes. J Intern Med. 2017;281(4):365-382.
32. Landgren O, Iskander K. Modern multiple myeloma therapy: deep, sustained treat- ment response and good clinical outcomes. J Intern Med. 2017;281(4):365-382.
33. Lonial S, Anderson KC. Association of response endpoints with survival outcomes in multiple myeloma. Leukemia. 2014;28(2):258-268.
34. Go RS, Bartley AC, Crowson CS, et al. Association Between Treatment Facility Volume and Mortality of Patients With Multiple Myeloma. J Clin Oncol. 2017;35(6):598-604.
35. Ailawadhi S, Advani P, Yang D, et al. Impact of access to NCI- and NCCN-designated cancer centers on outcomes for multiple myeloma patients: A SEER registry analysis. Cancer. 2016;122(4):618-625.
haematologica | 2018; 103(3)
513